Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy
Abstract Background There were few reports of postoperative radiotherapy (PORT) in stage pIII-N2 Non-small-cell Lung Cancer (NSCLC) patients receiving pneumonectomy followed by adjuvant chemotherapy. This study aims to evaluate safety and efficacy of PORT among these patients. Methods Between Jan. 2...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-5692-3 |
| _version_ | 1818248446771986432 |
|---|---|
| author | Wenhui Wang Yu Men Jianyang Wang Zongmei Zhou Dongfu Chen Zefen Xiao Qinfu Feng Jima Lv Jun Liang Nan Bi Shugeng Gao Luhua Wang Zhouguang Hui |
| author_facet | Wenhui Wang Yu Men Jianyang Wang Zongmei Zhou Dongfu Chen Zefen Xiao Qinfu Feng Jima Lv Jun Liang Nan Bi Shugeng Gao Luhua Wang Zhouguang Hui |
| author_sort | Wenhui Wang |
| collection | DOAJ |
| description | Abstract Background There were few reports of postoperative radiotherapy (PORT) in stage pIII-N2 Non-small-cell Lung Cancer (NSCLC) patients receiving pneumonectomy followed by adjuvant chemotherapy. This study aims to evaluate safety and efficacy of PORT among these patients. Methods Between Jan. 2004 and Dec. 2015, stage pIII-N2 NSCLC patients receiving pneumonectomy and adjuvant chemotherapy with or without PORT in our institution were retrospectively reviewed. Results Totally 119 patients were included, 32 patients receiving adjuvant chemotherapy and PORT (PORT group) and 87 receiving adjuvant chemotherapy alone (Control group). There were more patients with non-R0 resection in PORT group than Control group (25% vs. 8%, p = 0.031). In PORT group, ≥Grade 2 radiation-induced pneumonitis was 2/32. No severe radiation-related heart injury was observed. There was no PORT-related death. Of all patients, median follow-up time was 25 months. Median overall survival time (mOS) and median disease-free survival time (mDFS) were 46 months and 15 months, respectively. The PORT group had significantly better OS (not reached vs. 34 months, p = 0.003), DFS (19 months vs. 13 months, p = 0.024), local recurrence free survival (LRFS, p = 0.012), and distant metastasis free survival (DMFS, p = 0.047) than the Control group. As for failure pattern, PORT significantly reduced local regional failure rate (39.1% vs. 15.6%, p = 0.016). In subgroup analysis, patients with R0 resection (n = 104), OS and LRFS in PORT group were significantly longer, and PORT tended to increase DFS and DMFS. Conclusion For patients with stage pIII-N2 NSCLC after pneumonectomy and adjuvant chemotherapy, PORT can improve OS, DFS, LRFS and DMFS with tolerable toxicity. |
| first_indexed | 2024-12-12T15:20:44Z |
| format | Article |
| id | doaj.art-f32d9af0c96b4f9886939b7365e17e12 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-12T15:20:44Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-f32d9af0c96b4f9886939b7365e17e122022-12-22T00:20:24ZengBMCBMC Cancer1471-24072019-05-011911810.1186/s12885-019-5692-3Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomyWenhui Wang0Yu Men1Jianyang Wang2Zongmei Zhou3Dongfu Chen4Zefen Xiao5Qinfu Feng6Jima Lv7Jun Liang8Nan Bi9Shugeng Gao10Luhua Wang11Zhouguang Hui12Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Thoracic Surgery, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical CollegeAbstract Background There were few reports of postoperative radiotherapy (PORT) in stage pIII-N2 Non-small-cell Lung Cancer (NSCLC) patients receiving pneumonectomy followed by adjuvant chemotherapy. This study aims to evaluate safety and efficacy of PORT among these patients. Methods Between Jan. 2004 and Dec. 2015, stage pIII-N2 NSCLC patients receiving pneumonectomy and adjuvant chemotherapy with or without PORT in our institution were retrospectively reviewed. Results Totally 119 patients were included, 32 patients receiving adjuvant chemotherapy and PORT (PORT group) and 87 receiving adjuvant chemotherapy alone (Control group). There were more patients with non-R0 resection in PORT group than Control group (25% vs. 8%, p = 0.031). In PORT group, ≥Grade 2 radiation-induced pneumonitis was 2/32. No severe radiation-related heart injury was observed. There was no PORT-related death. Of all patients, median follow-up time was 25 months. Median overall survival time (mOS) and median disease-free survival time (mDFS) were 46 months and 15 months, respectively. The PORT group had significantly better OS (not reached vs. 34 months, p = 0.003), DFS (19 months vs. 13 months, p = 0.024), local recurrence free survival (LRFS, p = 0.012), and distant metastasis free survival (DMFS, p = 0.047) than the Control group. As for failure pattern, PORT significantly reduced local regional failure rate (39.1% vs. 15.6%, p = 0.016). In subgroup analysis, patients with R0 resection (n = 104), OS and LRFS in PORT group were significantly longer, and PORT tended to increase DFS and DMFS. Conclusion For patients with stage pIII-N2 NSCLC after pneumonectomy and adjuvant chemotherapy, PORT can improve OS, DFS, LRFS and DMFS with tolerable toxicity.http://link.springer.com/article/10.1186/s12885-019-5692-3Non-small-cell lung cancerStage pIII-N2PneumonectomyPostoperative radiotherapy |
| spellingShingle | Wenhui Wang Yu Men Jianyang Wang Zongmei Zhou Dongfu Chen Zefen Xiao Qinfu Feng Jima Lv Jun Liang Nan Bi Shugeng Gao Luhua Wang Zhouguang Hui Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy BMC Cancer Non-small-cell lung cancer Stage pIII-N2 Pneumonectomy Postoperative radiotherapy |
| title | Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy |
| title_full | Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy |
| title_fullStr | Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy |
| title_full_unstemmed | Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy |
| title_short | Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy |
| title_sort | postoperative radiotherapy is effective in improving survival of patients with stage piii n2 non small cell lung cancer after pneumonectomy |
| topic | Non-small-cell lung cancer Stage pIII-N2 Pneumonectomy Postoperative radiotherapy |
| url | http://link.springer.com/article/10.1186/s12885-019-5692-3 |
| work_keys_str_mv | AT wenhuiwang postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT yumen postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT jianyangwang postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT zongmeizhou postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT dongfuchen postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT zefenxiao postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT qinfufeng postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT jimalv postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT junliang postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT nanbi postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT shugenggao postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT luhuawang postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy AT zhouguanghui postoperativeradiotherapyiseffectiveinimprovingsurvivalofpatientswithstagepiiin2nonsmallcelllungcancerafterpneumonectomy |